Journal Article

Impact of telemedical management on hospitalization and mortality in heart failure patients with diabetes: a post-hoc subgroup analysis of the TIM-HF2 trial

Paar, W.Dieter, Dessapt-Baradez, Cécile, Wegscheider, Karl, Schütt, Katharina, Vettorazzi, Eik, Melzer, Christoph, Koehler, Kerstin, Müller-Wieland, Dirk, Vijayan, Anjaly, Lezius, Susanne, Koehler, Friedrich, Bramlage, Peter, Spethmann, Sebastian, Iakoubov, Roman, Koehler, Johanna, Winkler, Sebastian

2024

Overview

Background The TIM-HF2 study demonstrated that remote patient management (RPM) in a well-defined heart failure (HF) population reduced the percentage of days lost due to unplanned cardiovascular hospital admissions or all-cause death during 1-year follow-up (hazard ratio 0.80) and all-cause mortality alone (HR 0.70). Higher rates of hospital admissions and mortality have been reported in HF patients with diabetes compared with HF patients without diabetes. Therefore, in a post-hoc analysis of the TIM-HF2 study, we investigated the efficacy of RPM in HF patients with diabetes. Methods TIM-HF2 study was a randomized, controlled, unmasked (concealed randomization), multicentre trial, performed in Germany between August 2013 and May 2018. HF-Patients in NYHA class II/III who had a HF-related hospital admission within the previous 12 months, irrespective of left ventricular ejection fraction, and were randomized to usual care with or without added RPM and followed for 1 year. The primary endpoint was days lost due to unplanned cardiovascular hospitalization or due to death of any cause. This post-hoc analysis included 707 HF patients with diabetes. Results In HF patients with diabetes, RPM reduced the percentage of days lost due to cardiovascular hospitalization or death compared with usual care (HR 0.66, 95% CI 0.48–0.90), and the rate of all-cause mortality alone (HR 0.52, 95% CI 0.32–0.85). RPM was also associated with an improvement in quality of life (mean difference in change in global score of Minnesota Living with Heart Failure Questionnaire score (MLHFQ): − 3.4, 95% CI − 6.2 to − 0.6). Conclusion These results support the use of RPM in HF patients with diabetes. Clinical trial registration ClinicalTrials.gov NCT01878630.

• Publisher: BioMed Central,Springer Nature B.V,BMC
• Subject: Aged / Aged, 80 and over / Angiology / Antidiabetics / Blood pressure / Cardiology / Cardiovascular disease / Cause of Death / Clinical outcomes / Comorbidity / Congestive heart failure / Death / Diabetes / Diabetes mellitus / Diabetes Mellitus - diagnosis / Diabetes Mellitus - mortality / Diabetes Mellitus - therapy / Family physicians / Female / Germany - epidemiology / Heart failure / Heart Failure - diagnosis / Heart Failure - mortality / Heart Failure - physiopathology / Heart Failure - therapy / Hospitalization / Humans / Male / Medicine / Medicine & Public Health / Middle Aged / Mortality / Patient Admission / Patient admissions / Patients / Quality of life / Remote patient management / Risk Factors / Telehealth / Telemedicine / Time Factors / Treatment Outcome / Virtual private networks